查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1889414

奈米免疫疗法递送市场预测至2032年：按奈米载体类型、标靶化机制、治疗方式、给药途径、最终用户和地区分類的全球分析

Nano-Immunotherapy Delivery Market Forecasts to 2032 - Global Analysis By Nanocarrier Type, Targeting Mechanism, Therapeutic Modality, Administration Route, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的一项研究，预计到 2025 年，全球奈米免疫疗法递送市场价值将达到 31 亿美元，到 2032 年将达到 38 亿美元，在预测期内以 3% 的复合年增长率增长。

奈米免疫疗法递送系统利用奈米载体将免疫调节剂直接输送到目标细胞和组织。这些载体通常是经过工程改造的奈米颗粒，能够提高药物稳定性、实现精准标靶化和可控释放。透过将治疗药物集中于特定的免疫通路，它们可以增强疗效并最大限度地减少副作用。潜在应用包括癌症治疗、自体免疫疾病的调控、提升疫苗效力。奈米免疫疗法递送体现了奈米技术与免疫学的融合，能够为复杂疾病的治疗提供高度个人化和高效的干预手段。

据癌症研究组织称，脂质奈米颗粒递送系统已在 mRNA 疫苗中成功应用，目前已成为标靶固态肿瘤免疫疗法的领先平台，正在进行 120 多项临床试验。

对标靶免疫调节的需求日益增长

市场成长的驱动力在于对标靶免疫调节日益增长的需求，这种疗法能够精准控制癌症、自体免疫疾病和感染疾病中的免疫反应。奈米递送系统可达到局部作用，提高治疗效果，同时减少全身性副作用。奈米载体设计的进步，包括脂质奈米颗粒和聚合物系统，使得细胞激素、抗体和疫苗的个人化递送成为可能。全球向精准医疗的转型进一步强化了这项需求，使奈米免疫疗法成为下一代医疗解决方案的关键工具。

奈米颗粒生物相容性的复杂性

奈米颗粒生物相容性的复杂性是其发展的主要阻碍因素。奈米载体必须能够安全地与生物系统相互作用，同时避免免疫排斥、毒性或意外的生物分布。在保持治疗效果的同时实现体内稳定性需要精密的工程设计和广泛的检验。由于长期安全性数据有限，监管障碍进一步阻碍了商业化进程。这些挑战增加了研发成本，延缓了临床应用，使得生物相容性成为奈米免疫疗法在各种治疗应用中大规模推广应用的一大障碍。

免疫奈米载体平台的进展

免疫奈米载体平台的发展蕴藏着巨大的机会，这些平台能够实现多功能药物、疫苗和遗传物质的递送。混合奈米载体、外泌体仿生系统和刺激响应型设计的创新正在拓展治疗的可能性。这些平台可以同时标靶化免疫细胞、调节微环境并增强细胞内运输。随着研究的加速，免疫奈米载体有望彻底改变治疗策略，并为癌症、感染疾病和自体免疫疾病提供更安全、更有效、更个人化的解决方案。

长期毒性方面的安全隐患

奈米颗粒的长期毒性引发了市场安全的担忧。器官蓄积、意外的免疫反应以及慢性暴露的风险已引起监管机构和临床医生的警惕。由于纵向资料有限，难以全面评估其安全性，导致核准和广泛应用延迟。大众对奈米药物安全性的认知也影响市场成长。透过严格的测试、透明的报告和先进的生物相容性设计来解决这些担忧，对于降低风险和维持大众对奈米免疫疗法的信心至关重要。

新冠疫情的影响：

新冠疫情加速了奈米免疫疗法递送技术的应用，尤其是用于mRNA疫苗的脂质奈米颗粒。疫情表明，奈米载体平台具有扩充性、安全性和快速免疫接种的有效性。这项成功刺激了对奈米递送技术的投资，以期将其应用于更广泛的免疫疗法领域。疫情过后，市场受益于人们对免疫调节的认识提高以及对未来疫情爆发的准备。这场危机最终增强了人们对奈米医学的信心，并将奈米免疫疗法递送技术确立为现代医疗创新的基石。

预计在预测期内，脂质奈米颗粒（LNP）细分市场将占据最大的市场份额。

由于脂质奈米颗粒（LNP）在疫苗递送和治疗应用方面已取得显着成功，预计在预测期内，LNP细分市场将占据最大的市场份额。 LNP具有良好的生物相容性、扩充性以及对核酸和蛋白质的高效封装能力。其在新冠疫苗中的广泛应用证明了其可靠性，并加速了其在肿瘤学和自体免疫疾病治疗领域的应用。随着市场对安全且用途广泛的奈米载体的需求不断增长，LNP将继续保持领先地位，并在预测期内巩固其作为市场份额最大贡献者的地位。

预计在预测期内，活性配体介导的标靶治疗领域将实现最高的复合年增长率。

由于其能够将奈米载体精准靶向特定免疫细胞和组织，活性配体介导靶向技术预计将在预测期内实现最高增长率。连接抗体、胜肽和适配体等配体可增强治疗效果并减少脱靶效应。配体设计和受体分析技术的进步正在拓展其在癌症免疫疗法和自体免疫疾病管理中的应用。这种高特异性使得配体介导标靶技术成为奈米免疫疗法递送领域成长最快的细分市场。

占比最大的地区：

预计亚太地区将在预测期内占据最大的市场份额。这主要得益于其不断完善的医疗基础设施、日益​​普遍的慢性病以及政府对生物技术的大力支持。中国、日本和印度等国家正大力投资奈米医学研究和临床试验。成本效益高的生产方式和不断增长的患者群体进一步巩固了该地区的优势。随着先进治疗方法的日益普及，亚太地区将继续保持其作为奈米免疫疗法递送领先中心的地位，推动大规模商业化并巩固其市场领导地位。

复合年增长率最高的地区：

在预测期内，北美预计将实现最高的复合年增长率，这主要得益于先进的研发能力、健全的法规结构以及奈米医学的早期应用。美国在免疫疗法、临床试验和生技Start-Ups方面投入巨资，主导。癌症和自体免疫疾病的高发生率推动了精准医疗的需求。有利的报销政策以及与医疗保健系统的整合将进一步促进成长。在创新和基础设施的驱动下，北美有望成为奈米免疫疗法递送市场成长最快的地区。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 公司概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要参与者（最多3家公司）的SWOT分析
  • 区域细分
    • 根据客户要求，对主要国家的市场规模和复合年增长率进行估算和预测（註：可行性需确认）。
  • 竞争基准化分析
    • 根据主要参与者的产品系列、地理覆盖范围和策略联盟基准化分析

目录

第一章执行摘要

第二章 前言

  • 摘要
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球奈米免疫疗法递送市场（以奈米载体类型划分）

  • 脂质奈米颗粒（LNPs）
  • 聚合物奈米粒子
  • 蛋白质/胜肽奈米载体
  • 无机奈米颗粒（金、二氧化硅）
  • 外泌体和囊泡递送
  • 混合多功能奈米载体

6. 全球奈米免疫疗法递送市场按标靶化机制划分

  • 被动肿瘤标靶化（EPR效应）
  • 活性配体介导的靶向
  • 刺激响应释放系统
  • 细胞定向递送（抗原呈现细胞/T细胞）
  • 细胞内运输促进剂
  • 免疫微环境调节因子

7. 全球奈米免疫疗法递送市场依治疗方式划分

  • 癌症免疫疗法递送
  • 疫苗和佐剂递送
  • 自体免疫调节疗法
  • 过继细胞治疗支持系统
  • 基因编辑和基于RNA的免疫疗法
  • 复合奈米治疗平台

8. 全球奈米免疫疗法递送市场（依给药途径划分）

  • 静脉输液系统
  • 瘤内及局部给药
  • 吸入和肺部给药
  • 口腔和黏膜奈米递送
  • 经皮微针平台
  • 嵌入式仓库系统

9. 全球奈米免疫疗法递送市场（按最终用户划分）

  • 製药和生物技术公司
  • 学术和临床研究中心
  • 医院/肿瘤中心
  • 合约研发生产组织（CDMO）
  • 其他最终用户

10. 全球奈米免疫疗法递送市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章 企业概况

  • Moderna
  • BioNTech
  • Pfizer
  • AstraZeneca
  • Novartis
  • Sanofi
  • Johnson &Johnson
  • Gilead Sciences
  • Roche
  • Merck
  • Bayer
  • Takeda
  • BD Biosciences
  • Thermo Fisher Scientific
  • Danaher
  • Catalent
  • Evonik Health Care
  • Precision NanoSystems
Product Code: SMRC32787

According to Stratistics MRC, the Global Nano-Immunotherapy Delivery Market is accounted for $3.1 billion in 2025 and is expected to reach $3.8 billion by 2032 growing at a CAGR of 3% during the forecast period. Nano-Immunotherapy Delivery systems use nanoscale carriers to transport immune-modulating agents directly to targeted cells or tissues. These carriers, often engineered nanoparticles, enhance drug stability, precision targeting, and controlled release. By focusing therapeutic payloads on specific immune pathways, they improve efficacy while minimizing side effects. Applications include cancer treatment, autoimmune regulation, and vaccine enhancement. Nano-immunotherapy delivery represents a fusion of nanotechnology and immunology, enabling highly personalized and efficient interventions in complex disease management.

According to the Cancer Research Institute, lipid nanoparticle delivery systems, proven by their success in mRNA vaccines, are now the leading platform for targeted solid-tumor immunotherapy, with over 120 clinical trials currently underway.

Market Dynamics:

Driver:

Rising demand for targeted immunomodulation

The market is driven by increasing demand for targeted immunomodulation, enabling precise control of immune responses in cancer, autoimmune, and infectious diseases. Nano-delivery systems allow localized action, reducing systemic side effects and improving therapeutic efficacy. Advances in nanocarrier design, including lipid nanoparticles and polymeric systems, support tailored delivery of cytokines, antibodies, and vaccines. This demand is reinforced by the global shift toward precision medicine, positioning nano-immunotherapy as a critical tool for next-generation healthcare solutions.

Restraint:

Complexity of nanoparticle biocompatibility

A major restraint is the complexity of ensuring nanoparticle biocompatibility. Nano-carriers must interact safely with biological systems, avoiding immune rejection, toxicity, or unintended biodistribution. Achieving stability in vivo while maintaining therapeutic efficacy requires advanced engineering and extensive validation. Regulatory hurdles further complicate commercialization, as long-term safety data is limited. These challenges increase development costs and slow clinical adoption, making biocompatibility a critical barrier to scaling nano-immunotherapy delivery across diverse therapeutic applications.

Opportunity:

Advances in immune nanocarrier platforms

Significant opportunity lies in advances in immune nanocarrier platforms, which enable multifunctional delivery of drugs, vaccines, and genetic material. Innovations in hybrid nanocarriers, exosome-inspired systems, and stimuli-responsive designs are expanding therapeutic potential. These platforms can simultaneously target immune cells, modulate microenvironments, and enhance intracellular trafficking. As research accelerates, immune nanocarriers are poised to revolutionize treatment strategies, offering safer, more effective, and personalized solutions for oncology, infectious diseases, and autoimmune disorders.

Threat:

Safety concerns around long-term toxicity

The market faces threats from safety concerns related to long-term nanoparticle toxicity. Accumulation in organs, unforeseen immune reactions, and chronic exposure risks raise caution among regulators and clinicians. Limited longitudinal data makes it difficult to fully assess safety profiles, slowing approvals and adoption. Public perception of nanomedicine safety also influences market growth. Addressing these concerns through rigorous testing, transparent reporting, and advanced biocompatible designs is essential to mitigate risks and sustain confidence in nano-immunotherapy delivery.

Covid-19 Impact:

Covid-19 accelerated adoption of nano-immunotherapy delivery, particularly lipid nanoparticles used in mRNA vaccines. The pandemic validated nanocarrier platforms as scalable, safe, and effective for rapid immunization. This success boosted investment in nano-delivery technologies for broader immunotherapy applications. Post-pandemic, the market benefits from heightened awareness of immune modulation and preparedness for future outbreaks. The crisis ultimately strengthened confidence in nanomedicine, positioning nano-immunotherapy delivery as a cornerstone of modern healthcare innovation.

The lipid nanoparticles (LNPs) segment is expected to be the largest during the forecast period

The lipid nanoparticles (LNPs) segment is expected to account for the largest market share during the forecast period, driven by their proven success in vaccine delivery and therapeutic applications. LNPs offer biocompatibility, scalability, and efficient encapsulation of nucleic acids and proteins. Their widespread use in Covid-19 vaccines demonstrated reliability, accelerating adoption in oncology and autoimmune therapies. As demand for safe, versatile nanocarriers grows, LNPs remain the dominant choice, securing their position as the largest contributor to market share during the forecast period.

The active ligand-mediated targeting segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the active ligand-mediated targeting segment is predicted to witness the highest growth rate, propelled by its precision in directing nanocarriers to specific immune cells or tissues. By attaching ligands such as antibodies, peptides, or aptamers, these systems enhance therapeutic efficacy and reduce off-target effects. Advances in ligand engineering and receptor profiling are expanding applications in cancer immunotherapy and autoimmune disease management. This high specificity positions ligand-mediated targeting as the fastest-growing segment in nano-immunotherapy delivery.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, attributed to expanding healthcare infrastructure, rising prevalence of chronic diseases, and strong government support for biotechnology. Countries like China, Japan, and India are investing heavily in nanomedicine research and clinical trials. Cost-effective manufacturing and growing patient populations further reinforce regional dominance. With increasing adoption of advanced therapies, Asia Pacific remains the leading hub for nano-immunotherapy delivery, driving large-scale commercialization and market leadership.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR supported by advanced R&D, strong regulatory frameworks, and early adoption of nanomedicine. The U.S. leads with robust investment in immunotherapy, clinical trials, and biotech startups. High prevalence of cancer and autoimmune disorders accelerates demand for precision therapies. Favorable reimbursement policies and integration with healthcare systems further strengthen growth. With innovation and infrastructure, North America is positioned as the fastest-growing region in the nano-immunotherapy delivery market.

Key players in the market

Some of the key players in Nano-Immunotherapy Delivery Market include Moderna, BioNTech, Pfizer, AstraZeneca, Novartis, Sanofi, Johnson & Johnson, Gilead Sciences, Roche, Merck, Bayer, Takeda, BD Biosciences, Thermo Fisher Scientific, Danaher, Catalent, Evonik Health Care, and Precision NanoSystems.

Key Developments:

In November 2025, Moderna unveiled its next-generation lipid nanoparticle (LNP) delivery platform for oncology immunotherapies. The innovation enables precise targeting of tumor microenvironments, offering rapid immune activation with improved safety profiles.

In October 2025, BioNTech launched its AI-enhanced nano-carrier system designed to optimize mRNA immunotherapy delivery. The system integrates adaptive algorithms to personalize dosing and improve therapeutic outcomes in cancer and autoimmune disorders.

In September 2025, Pfizer announced the rollout of its scalable nano-immunotherapy manufacturing suite to support global clinical trials. The facility focuses on advanced encapsulation technologies, ensuring consistent quality and faster translation from lab to patient care.

Nanocarrier Types Covered:

  • Lipid Nanoparticles (LNPs)
  • Polymeric Nanoparticles
  • Protein & Peptide-Based Nanocarriers
  • Inorganic Nanoparticles (Gold, Silica)
  • Exosome & Vesicle-Based Delivery
  • Hybrid Multifunctional Nanocarriers

Targeting Mechanisms Covered:

  • Passive Tumor Targeting (EPR Effect)
  • Active Ligand-Mediated Targeting
  • Stimuli-Responsive Release Systems
  • Cell-Directed Delivery (APCs/T Cells)
  • Intracellular Trafficking Enhancers
  • Immune Microenvironment Modulators

Therapeutic Modalities Covered:

  • Cancer Immunotherapy Delivery
  • Vaccine & Adjuvant Delivery
  • Autoimmune Modulation Therapies
  • Adoptive Cell Therapy Support Systems
  • Gene-Editing & RNA-based Immunotherapies
  • Combination Nanotherapy Platforms

Administration Routes Covered:

  • Intravenous Delivery Systems
  • Intratumoral & Localized Delivery
  • Inhalation & Pulmonary Delivery
  • Oral & Mucosal Nanodelivery
  • Transdermal & Microneedle Platforms
  • Implantable Depot Systems

End Users Covered:

  • Pharmaceutical & Biotech Companies
  • Academic & Clinical Research Centers
  • Hospitals & Oncology Centers
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nano-Immunotherapy Delivery Market, By Nanocarrier Type

  • 5.1 Introduction
  • 5.2 Lipid Nanoparticles (LNPs)
  • 5.3 Polymeric Nanoparticles
  • 5.4 Protein & Peptide-Based Nanocarriers
  • 5.5 Inorganic Nanoparticles (Gold, Silica)
  • 5.6 Exosome & Vesicle-Based Delivery
  • 5.7 Hybrid Multifunctional Nanocarriers

6 Global Nano-Immunotherapy Delivery Market, By Targeting Mechanism

  • 6.1 Introduction
  • 6.2 Passive Tumor Targeting (EPR Effect)
  • 6.3 Active Ligand-Mediated Targeting
  • 6.4 Stimuli-Responsive Release Systems
  • 6.5 Cell-Directed Delivery (APCs/T Cells)
  • 6.6 Intracellular Trafficking Enhancers
  • 6.7 Immune Microenvironment Modulators

7 Global Nano-Immunotherapy Delivery Market, By Therapeutic Modality

  • 7.1 Introduction
  • 7.2 Cancer Immunotherapy Delivery
  • 7.3 Vaccine & Adjuvant Delivery
  • 7.4 Autoimmune Modulation Therapies
  • 7.5 Adoptive Cell Therapy Support Systems
  • 7.6 Gene-Editing & RNA-based Immunotherapies
  • 7.7 Combination Nanotherapy Platforms

8 Global Nano-Immunotherapy Delivery Market, By Administration Route

  • 8.1 Introduction
  • 8.2 Intravenous Delivery Systems
  • 8.3 Intratumoral & Localized Delivery
  • 8.4 Inhalation & Pulmonary Delivery
  • 8.5 Oral & Mucosal Nanodelivery
  • 8.6 Transdermal & Microneedle Platforms
  • 8.7 Implantable Depot Systems

9 Global Nano-Immunotherapy Delivery Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical & Biotech Companies
  • 9.3 Academic & Clinical Research Centers
  • 9.4 Hospitals & Oncology Centers
  • 9.5 Contract Development & Manufacturing Organizations (CDMOs)
  • 9.6 Other End Users

10 Global Nano-Immunotherapy Delivery Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Moderna
  • 12.2 BioNTech
  • 12.3 Pfizer
  • 12.4 AstraZeneca
  • 12.5 Novartis
  • 12.6 Sanofi
  • 12.7 Johnson & Johnson
  • 12.8 Gilead Sciences
  • 12.9 Roche
  • 12.10 Merck
  • 12.11 Bayer
  • 12.12 Takeda
  • 12.13 BD Biosciences
  • 12.14 Thermo Fisher Scientific
  • 12.15 Danaher
  • 12.16 Catalent
  • 12.17 Evonik Health Care
  • 12.18 Precision NanoSystems

List of Tables

  • Table 1 Global Nano-Immunotherapy Delivery Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Nano-Immunotherapy Delivery Market Outlook, By Nanocarrier Type (2024-2032) ($MN)
  • Table 3 Global Nano-Immunotherapy Delivery Market Outlook, By Lipid Nanoparticles (LNPs) (2024-2032) ($MN)
  • Table 4 Global Nano-Immunotherapy Delivery Market Outlook, By Polymeric Nanoparticles (2024-2032) ($MN)
  • Table 5 Global Nano-Immunotherapy Delivery Market Outlook, By Protein & Peptide-Based Nanocarriers (2024-2032) ($MN)
  • Table 6 Global Nano-Immunotherapy Delivery Market Outlook, By Inorganic Nanoparticles (Gold, Silica) (2024-2032) ($MN)
  • Table 7 Global Nano-Immunotherapy Delivery Market Outlook, By Exosome & Vesicle-Based Delivery (2024-2032) ($MN)
  • Table 8 Global Nano-Immunotherapy Delivery Market Outlook, By Hybrid Multifunctional Nanocarriers (2024-2032) ($MN)
  • Table 9 Global Nano-Immunotherapy Delivery Market Outlook, By Targeting Mechanism (2024-2032) ($MN)
  • Table 10 Global Nano-Immunotherapy Delivery Market Outlook, By Passive Tumor Targeting (EPR Effect) (2024-2032) ($MN)
  • Table 11 Global Nano-Immunotherapy Delivery Market Outlook, By Active Ligand-Mediated Targeting (2024-2032) ($MN)
  • Table 12 Global Nano-Immunotherapy Delivery Market Outlook, By Stimuli-Responsive Release Systems (2024-2032) ($MN)
  • Table 13 Global Nano-Immunotherapy Delivery Market Outlook, By Cell-Directed Delivery (APCs/T Cells) (2024-2032) ($MN)
  • Table 14 Global Nano-Immunotherapy Delivery Market Outlook, By Intracellular Trafficking Enhancers (2024-2032) ($MN)
  • Table 15 Global Nano-Immunotherapy Delivery Market Outlook, By Immune Microenvironment Modulators (2024-2032) ($MN)
  • Table 16 Global Nano-Immunotherapy Delivery Market Outlook, By Therapeutic Modality (2024-2032) ($MN)
  • Table 17 Global Nano-Immunotherapy Delivery Market Outlook, By Cancer Immunotherapy Delivery (2024-2032) ($MN)
  • Table 18 Global Nano-Immunotherapy Delivery Market Outlook, By Vaccine & Adjuvant Delivery (2024-2032) ($MN)
  • Table 19 Global Nano-Immunotherapy Delivery Market Outlook, By Autoimmune Modulation Therapies (2024-2032) ($MN)
  • Table 20 Global Nano-Immunotherapy Delivery Market Outlook, By Adoptive Cell Therapy Support Systems (2024-2032) ($MN)
  • Table 21 Global Nano-Immunotherapy Delivery Market Outlook, By Gene-Editing & RNA-based Immunotherapies (2024-2032) ($MN)
  • Table 22 Global Nano-Immunotherapy Delivery Market Outlook, By Combination Nanotherapy Platforms (2024-2032) ($MN)
  • Table 23 Global Nano-Immunotherapy Delivery Market Outlook, By Administration Route (2024-2032) ($MN)
  • Table 24 Global Nano-Immunotherapy Delivery Market Outlook, By Intravenous Delivery Systems (2024-2032) ($MN)
  • Table 25 Global Nano-Immunotherapy Delivery Market Outlook, By Intratumoral & Localized Delivery (2024-2032) ($MN)
  • Table 26 Global Nano-Immunotherapy Delivery Market Outlook, By Inhalation & Pulmonary Delivery (2024-2032) ($MN)
  • Table 27 Global Nano-Immunotherapy Delivery Market Outlook, By Oral & Mucosal Nanodelivery (2024-2032) ($MN)
  • Table 28 Global Nano-Immunotherapy Delivery Market Outlook, By Transdermal & Microneedle Platforms (2024-2032) ($MN)
  • Table 29 Global Nano-Immunotherapy Delivery Market Outlook, By Implantable Depot Systems (2024-2032) ($MN)
  • Table 30 Global Nano-Immunotherapy Delivery Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Nano-Immunotherapy Delivery Market Outlook, By Pharmaceutical & Biotech Companies (2024-2032) ($MN)
  • Table 32 Global Nano-Immunotherapy Delivery Market Outlook, By Academic & Clinical Research Centers (2024-2032) ($MN)
  • Table 33 Global Nano-Immunotherapy Delivery Market Outlook, By Hospitals & Oncology Centers (2024-2032) ($MN)
  • Table 34 Global Nano-Immunotherapy Delivery Market Outlook, By Contract Development & Manufacturing Organizations (CDMOs) (2024-2032) ($MN)
  • Table 35 Global Nano-Immunotherapy Delivery Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.